We are monitoring the impact of COVID-19 & Recession alarm on MEA Kidney Cancer Diagnostics And Therapeutics Market Get in touch with us for detailed analysis Know More
Share on

Middle East & Africa Kidney Cancer Diagnostics and Therapeutics Market Research Report - Segmented By Type, Tests & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis, Size, Share, Growth, Trends & Forecasts (2022 to 2027)

Published: January, 2022
ID: 790
Pages: 138

MEA Kidney Cancer Diagnostics and Therapeutics Market Size (2022 to 2027)

The Middle East and Africa Kidney Cancer Diagnostics and Therapeutics Market was worth USD 0.18 billion in 2022 and estimated to be growing at a CAGR of 5.15%, to reach USD 0.23 billion by 2027.

The rising number of kidney cancer deaths weighs heavily on regional government as people demand accurate diagnosis and treatment for this critical disease. Some of the factors influencing the growth of the MEA kidney cancer diagnosis and therapeutics market include increased presence of carcinogens in common consumables, high exposure to toxic substances in factories and industrial environments, lack of knowledge about causative agents, symptoms, and preventive measures against kidney cancer, increased health care costs and deterred end-stage kidney cancer patients from seeking an optimal diagnosis.

With the increasing incidence of kidney cancer, there is a high demand for accessible and affordable diagnostic and treatment procedures. According to the GLOBOCAN statistics, over 175,000 people died from kidney cancer and its complications in 2018. These numbers represent nearly 1.82% of total cancer deaths across the globe. As kidney cancer research organizations and companies struggle to develop effective drugs due to tight budgets, governments and international authorities offer funds and grants to support the market.

Several international companies are looking into regional expansion and new products in unmet market regions. All these activities drive the overall growth of the MEA kidney cancer diagnostics and therapeutics market.

Kidney cancer patients are often faced with delayed diagnosis due to the unstable nature of this type of cancer. Many patients with kidney cancer are diagnosed at the end stage, which reduces the options for various treatments. This can be a limiting factor for the growth of the MEA kidney cancer diagnosis and treatment market. Other factors such as the low success rate of cancer medication, lack of funds for clinical trials, and stringent regulatory issues for approvals will cause the market to slow down in the years to come. The burden of monitoring kidney cancer incidence shifts to hospitals and medical research organizations as they strive to develop new diagnostic and therapeutic procedures. This calls into question the market's growth rate, especially in remote areas of the MEA region.

This research report on the MEA kidney cancer diagnostics and therapeutics market has been segmented and sub-segmented into the following categories:

By Type:

  • Transitional Cell Cancer
  • Renal Cell Carcinoma
  • Renal Sarcoma
  • Others

By Tests:

  • Biopsy
  • CT Scan
  • Cystoscopy
  • Intravenous Pyelogram
  • Kidney Ultrasound

By Country:

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

In 2022, Saudi Arabia had the largest market share and was expected to offer significant growth opportunities in the MEA kidney cancer diagnostics and therapeutics market in the years to come. Various factors such as solid healthcare infrastructure, growing patient awareness, high presence of kidney disorders, increased availability of resources, cheap labor, and rapid manufacturing regulations will drive the market growth in this region. In Saudi Arabia, kidney cancer accounts for approximately 3.65% of all cancers in men and 2.22% in women. In the early 2000s, nearly 139 cases of kidney cancer were recorded, 55.32% in men and 44.61% in women. The incidence rate was recorded at 1.6 per 100,000 for men and 1.3 per 100,000 for women.

Other regions such as the United Arab Emirates, Egypt, South Africa, Qatar, and Turkey will grow steadily due to improving healthcare facilities, supportive reimbursement policies, early availability, and adoption of the latest diagnostics and therapeutics devices for kidney cancer.

KEY MARKET PLAYERS:

Companies playing an influential role in the MEA kidney cancer diagnostics and therapeutics market profiled in this report are GlaxoSmithKline, Bayer, Pfizer, Sanofi S.A, Hoffmann La Roche, Novartis, and Abbott Laboratories.

1.Introduction                              

              1.1 Market Definition                  

              1.2 Study Deliverables                

              1.3 Base Currency, Base Year and Forecast Periods                       

              1.4 General Study Assumptions              

2. Research Methodology                                       

              2.1 Introduction                           

              2.2 Research Phases                    

                             2.2.1 Secondary Research          

                             2.2.2 Primary Research

                             2.2.3 Econometric Modelling     

                             2.2.4 Expert Validation 

              2.3 Analysis Design                      

              2.4 Study Timeline                       

3. Overview                                   

              3.1 Executive Summary              

              3.2 Key Inferences                       

              3.3 New Developments              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                

              4.1 Market Drivers                       

              4.2 Market Restraints                  

              4.3 Key Challenges                       

              4.4 Current Opportunities in the Market                           

5. Market Segmentation                                          

              5.1 By Type                     

                             5.1.1 Transitional Cell Cancer    

                             5.1.2 Renal cell carcinoma         

                             5.1.3 Renal sarcoma     

                             5.1.4 Other Cancers      

              5.2 By Tests                     

                             5.2.1 Biopsy      

                             5.2.2 CT Scan    

                             5.2.3 Cystoscopy            

                             5.2.4 Intravenous pyelogram    

                             5.2.5 Kidney Ultrasound             

6. Geographical Analysis                                         

              6.1 Introduction                           

              6.2 Middle-East                            

              6.3 Africa                         

7. Pipeline Product Analysis                                    

              7.1 Overview                                 

              7.2 Pipeline Development Landscape                                 

              7.3 Molecular Targets in the Pipeline                                  

              7.4 Clinical Trials                          

                             7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target    

                             7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target             

                             7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.   

8.Strategic Analysis                                    

              8.1 PESTLE analysis                      

                             8.1.1 Political    

                             8.1.2 Economic

                             8.1.3 Social       

                             8.1.4 Technological       

                             8.1.5 Legal         

                             8.1.6 Environmental     

              8.2 Porter’s Five analysis                          

                             8.2.1 Bargaining Power of Suppliers       

                             8.2.2 Bargaining Power of Consumers   

                             8.2.3 Threat of New Entrants    

                             8.2.4 Threat of Substitute Products and Services             

                             8.2.5 Competitive Rivalry within the Industry     

9.Market Leaders' Analysis                                     

              9.1 GlaxoSmithKline                    

                             9.1.1 Overview 

                             9.1.2 Product Analysis  

                             9.1.3 Strategic Evaluation and Operations          

                             9.1.4 Financial analysis 

                             9.1.5 Legal issues           

                             9.1.6 Recent Developments       

                             9.1.7 SWOT analysis      

                             9.1.8 Analyst View         

              9.2 Bayer                         

              9.3 Pfizer                         

              9.4 Sanofi S.A                 

              9.5 Hoffmann La Roche              

              9.6 Novartis                    

              9.7 Abbott Laboratories                            

10.Competitive Landscape                                      

              10.1 Market share analysis                      

              10.2 Merger and Acquisition Analysis                  

              10.3 Agreements, collaborations and Joint Ventures                    

              10.4 New Product Launches                     

11.Expert Opinions                                    

              11.1 Market Outlook                   

              11.2 Investment Opportunities               

Appendix                                       

              a) List of Tables              

              b) List of Figures                           

  1. Middle East & Africa Kidney Cancer Diagnostics and Therapeutics Market By Region, From 2022 - 2027 (USD Billion)
  2. Middle East & Africa Kidney Cancer Diagnostics and Therapeutics Market By Type, From 2022 - 2027 (USD Billion)
  3. Middle East & Africa Transitional Cell Cancer Market By Region, From 2022 - 2027 (USD Billion)
  4. Middle East & Africa Renal cell carcinoma Market By Region, From 2022 - 2027 (USD Billion)
  5. Middle East & Africa Renal sarcoma Market By Region, From 2022 - 2027 (USD Billion)
  6. Middle East & Africa Other Kidney Cancers Market By Region, From 2022 - 2027 (USD Billion)
  7. Middle East & Africa Kidney Cancer Diagnostics and Therapeutics Market By Tests, From 2022 - 2027 (USD Billion)
  8. Middle East & Africa Biopsy Market By Region, From 2022 - 2027 (USD Billion)
  9. Middle East & Africa CT Scan Market By Region, From 2022 - 2027 (USD Billion)
  10. Middle East & Africa Cystoscopy Market By Region, From 2022 - 2027 (USD Billion)
  11. Middle East & Africa Intravenous pyelogram Market By Region, From 2022 - 2027 (USD Billion)
  12. Middle East & Africa Kidney Ultrasound Market By Region, From 2022 - 2027 (USD Billion)
  13. Middle East Kidney Cancer Diagnostics and Therapeutics Market By Type, From 2022 - 2027 (USD Billion)
  14. Middle East Kidney Cancer Diagnostics and Therapeutics Market By Tests, From 2022 - 2027 (USD Billion)
  15. Africa Kidney Cancer Diagnostics and Therapeutics Market By Type, From 2022 - 2027 (USD Billion)
  16. Africa Kidney Cancer Diagnostics and Therapeutics Market By Tests, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

2875


pdf excel
$

3220


pdf excel powerbi
$

4600


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2875

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample